A number of Xarelto lawsuits have been filed in U.S. courts that question some of the marketing statements used to drive sales of the drug.
New York, New York (PRWEB) October 21, 2014
As Xarelto lawsuits (http://www.thexareltolawsuit.com/) mount in courts around the U.S., Bernstein Liebhard LLP notes that a new study is raising serious questions about certain marketing claims made about the blood thinner. The study, which was published in the Journal of Cardiology on September 2, 2014, looked at 136 patients with non-valvular atrial fibrillation who were treated with rivaroxaban, sold as the brand name medication Xarelto. It was found that those patients who experienced peak levels of the drug in their blood for the greatest length of time were most likely to suffer major bleeding events. The authors of the study concluded that their findings suggested regularly monitoring the blood of patients treated with rivaroxaban might be useful in identifying those most at risk for serious internal bleeding.*
“According to court documents, a number of Xarelto lawsuits have been filed in U.S. courts that question some of the marketing statements used to drive sales of the drug. These include statements that Xarelto is superior to older blood thinners because, among other things, it does not require that patients undergo regular blood monitoring,” said Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering legal evaluations to people who allegedly suffered serious injuries from Xarelto, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.
Xarelto, known generically as rivaroxaban, was launched in the U.S. in 2011, and is now approved to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery. Like any blood thinner, the medication can sometimes cause patients to experience internal hemorrhaging. However, no antidote has yet been approved for Xarelto bleeding. **
Court records indicate that at least 21 Xarelto lawsuits are now pending in U.S. courts on behalf of patients who experienced uncontrollable bleeding and other side effects, allegedly due to their use of the blood thinner. On October 9th, plaintiffs in a number of these cases filed a Motion with the U.S. Judicial Panel on Multidistrict Litigation (JPML) seeking the establishment of a consolidated litigation in the U.S. District Court, Southern District of Illinois, for all federal product liability claims involving the medication. Among other things, the Motion points out that all of the cases filed thus far allege that Xarelto was wrongly marketed as an improvement over warfarin, a decades-old blood thinner that requires patients to undergo regular blood monitoring. While warfarin bleeding can be stopped via the administration of vitamin K, there is no approved antidote to stop Xarelto bleeding. (In Re: Xarelto Products Liability Litigation, No. 2592)
Individuals who suffered uncontrollable episodes of internal bleeding allegedly associated with Xarelto may be entitled to file their own Xarelto lawsuit. To learn more about complications potentially associated with Xarelto, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to schedule a free legal consultation.
*journal-of-cardiology.com/article/S0914-5087%2814%2900226-3/abstract, Journal of Cardiology, September 9, 2014
**fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP